Enhancing T cell therapies to fight cancer
Synthetic metabolism to armor and enhance a new class of cell therapies
['FUNDING_OTHER'] · GEORGIA INSTITUTE OF TECHNOLOGY · NIH-10472794
This study is looking at new ways to make T cell therapies for cancer work better by helping these immune cells fight off tumors more effectively, so they can get the nutrients they need and break down harmful substances made by the cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGIA INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10472794 on ClinicalTrials.gov |
What this research studies
This research focuses on improving T cell therapies for cancer treatment by addressing the ways tumors suppress the immune response. It aims to develop innovative methods using synthetic metabolism to enhance T cell function, allowing them to compete better with cancer cells for nutrients and to degrade harmful metabolic byproducts produced by tumors. By applying metabolic engineering and synthetic biology, the project seeks to create T cells that can thrive in the challenging tumor environment and effectively combat cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who are undergoing or considering T cell therapies.
Not a fit: Patients with non-solid tumors or those who do not have a suitable immune response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by improving the immune system's ability to fight tumors.
How similar studies have performed: While the approach of using synthetic metabolism in T cell therapies is innovative, similar strategies in enhancing immune responses have shown promise in preliminary studies.
Where this research is happening
ATLANTA, UNITED STATES
- GEORGIA INSTITUTE OF TECHNOLOGY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLAZECK, JOHN JAMES — GEORGIA INSTITUTE OF TECHNOLOGY
- Study coordinator: BLAZECK, JOHN JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer